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Mutation in the Gjb1 gene, coding for a connexin (Cx32), is associated with an inherited
peripheral neuropathic disorder (X-linked Charcot-Marie-Tooth, CMTX). Our previous work
reported that transgenic animals expressing a human Gjb1 transgene present polyploidy
and abnormal over-duplication of the centrosome, suggesting a role for Gjb1 in mitotic
stability. In this article, we propose mechanisms by which mutations in Gjb1 induce mitotic
instability and discuss its potential relation with the CMTX phenotype. We showed that
transgenic cells exhibit CamKII over-stimulation, a phenomenon that has been linked to
mitotic instability (polyploidy, nuclear volume and centrosome over-duplication), that is
reversed by CamKII inhibitors. We also demonstrate that connexon activity is partially
restored in transgenic cells with CamKII inhibitors. Our model supports the role for Pim1, a
kinase that has been associated with genomic instability in cancers, in genomic instability
in Cx32 mutations. Regarding in vivo phenotype, we showed that degradation on the
rotarod test in our transgenic mice is significantly lowered by treatment with a CamKII
inhibitor (KN93). This effect was seen in two lines with different point mutations in GJB1,
and stopping the treatment led to degradation of the phenotype.
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INTRODUCTION
X-linked Charcot-Marie-Tooth disease (CMTX) is an inherited
X-linked peripheral neuropathy (Dyck and Lambert, 1968; Hahn
et al., 1990; Martyn and Hughes, 1997), presenting both demyeli-
nating and axonal anomalies (Bergoffen et al., 1993; Hanemann
et al., 2003). CMTX is caused by mutations in the gene GJB1
(Bergoffen et al., 1993), located on the proximal long arm of
the X chromosome, that encodes connexin 32 (Cx32), a myelin
membrane protein found in the PNS and CNS (Scherer et al.,
1995). Cx32 is located in gap junctions and forms hexameric
hemichannels called connexons (Mese et al., 2007). The dock-
ing of two connexons across an intercellular gap triggers the
formation of a channel that connects the cytoplasm of adja-
cent cells (Abrams et al., 2001) allowing exchange of ions, small
molecules (<1000Da) and signaling effectors (Bennett et al.,
1991).
Less than 10% of the mutations observed in patients are null
alleles (De Jonghe et al., 1999; Abrams et al., 2001; Boerkel et al.,
2002; Wang et al., 2004; Bicego et al., 2006). The majority of
mutations correspond to a loss of function and could be classi-
fied into two categories: mutations affecting cell trafficking, where
the Cx32 protein is observed in the endoplasmic reticulum and/or
the Golgi but not in the cell membrane (Deschênes et al., 1997;
VanSlyke et al., 2000; Yum et al., 2002); and mutations affecting
connexon functions, where Cx32 is present in the cell membrane
but the connexon remains closed, thus preventing any exchange
between adjacent cells (Omori et al., 1996; Yoshimura et al., 1996;
Oh et al., 1997).
Models of CMTX have been already described, but either they
are based on gene invalidation (Nelles et al., 1996)—a situation
rarely observed in humans—or on a molecular construction that
puts Gjb1 expression under the control of an exogenous promoter
(Sargiannidou et al., 2009). We thus generated transgenic mouse
lines with BACs containing human GJB1 genes expressing either
the mutation G12S, observed in non-related CMTX families and
affecting trafficking of Cx32 (G12S) (Yum et al., 2002) or the
mutation S26L, affecting connexon activity (S26L) (Yoshimura
et al., 1996; Oh et al., 1997). Five transgenic lines were generated
and studied, which led to the observation of genomic instability
in transgenic cells and abnormalities of centrosome duplication.
These data suggested that Cx32 is involved in the control of
mitotic stability. In addition, we noticed that the transgenic ani-
mals presented abnormal behavior on the rotarod (Mones et al.,
2012).
www.frontiersin.org June 2014 | Volume 8 | Article 151 | 1
Mones et al. CamKII and Cx32 mutations
Calcium ionophores and CamKII over-expression affect
mitotic stability leading to centrosome over-duplication
(Matsumoto and Maller, 2002) in Xenopus oocytes. We hypoth-
esized that CamKII could be a downstream effector of Gjb1
anomalies. To test this, we used two transgenic lines: G2 (two
copies of the mutated BAC, presenting a mutation affecting cell
trafficking) and S3 (three copies of the mutated BAC, harboring
a mutation affecting connexon activity). We observed CamKII
over-stimulation in the transgenic cells leading to mitotic
instability, and reversal of this instability upon adding CamKII
inhibitors. We also observed partial restoration of connexon
activity upon addition of CamKII inhibitors in the transgenic
lines and in sciatic nerve organ cultures. Furthermore, we
demonstrated that degradation of the behavior phenotype of
our transgenic mice, observed on the rotarod, is significantly
improved by treatment with a CamKII inhibitor (KN93). We
extend our hypothesis that Pim1, a kinase that has been associ-
ated with genomic instability in cancers (Roh et al., 2003, 2005),
could also be involved in genomic instability in Cx32 mutations.
In this report, we draw upon the results of our work to discuss the
mechanism of Gjb1 mutations in oligodendrocyte maturation
and myelination that explains the observations reported in a
recent paper relating cellular phenotype and anomalies in glial
cells (Waggener et al., 2013).
MATERIALS AND METHODS
ETHICS STATEMENT
Animal experimentation was carried out in CEPA (Advanced
Physiological Studies Centre). CEPA has been agreed by
French National authorities, that is Departmental Directorate
of Protecting People (DDPP) and specifically Veterinary Service
(agreement N◦A13-055-27). CEPA is in charge of observance
of ethical rules of our ethic committee and, in this case, it is
not necessary to have a special permit to achieve rotarod per-
formance tests on mice. Animals have been sacrificed using an
excess of anesthetic administration (Isoflurane) as recommended
by European and National Guidelines in order to minimize
suffering.
GENERATION OF TRANSGENIC LINES
BAC modifications were generated by Gene Bridges GmbH
Heidelberg using recombineering technology. BAC DNA was iso-
lated from preparative pulsed field gels using a modification of
a previously described method (Huxley et al., 1996). Transgenic
mice were generated using the standard technique of pronu-
clear injection using C57BL/6J—CBA/Ca F1 mice as donors.
Subsequent crosses were to the same F1 mice.
CELL CULTURE
For the isolation of fibroblasts a small fragment of mouse
ear was removed, dipped in alcohol solution, cut into small
pieces in a sterile Petri dish in the presence of PBS contain-
ing fungicide (fonigizon) diluted 1/250, and transferred to 2-ml
tubes containing 1ml dissociation buffer (DMEM plus 20%
FBS, 1mg/ml BSA, 0.5mg/ml collagenase, 0.25mg/ml trypsin
and penicillin/streptomycin). The tubes were incubated in a
FIGURE 1 | Fibroblasts from wild type mice (WT) or transgenic lines
(G2 or S3) were collected and cultured. (A) Protein extract was obtained
from WT and S3 fibroblasts, western blotted and probed with an antibody
against phosphorylated CamKII. (B) Proteins from fibroblasts from either
WT animals or S3 transgenic animals have been analyzed on an acrylamide
gel and blotted. Membrane have been the probed with an antibody directed
toward the phosphorylated form of CamKII. ∗∗∗p-value < 0.001.
water bath with agitation for 1 h at 37◦C. Fibroblast medium
(DMEM, 10% FBS, 2mM Gln, 100U/ml penicillin, 100μg/ml
streptomycin) was added to each tube and the samples were
centrifuged at 400 g for 10min. The cells were re-suspended in
fibroblast medium, seeded into Petri dishes and placed in an incu-
bator at 37◦C, 5% CO2. The culture medium was replaced every
2 days. When the cultures reached sub-confluence, the cells were
trypsinized and expanded into tissue culture flasks. All experi-
ments were performed using cells between passage numbers four
and eight.
WESTERN BLOTTING
Cells were lysed in RIPA buffer (50mM Tris-Cl pH 7.4,
1% NP40, 0.25% sodium deoxycholate, 0.1% SDS, 150mM
sodium chloride) supplemented with protease and phosphatase
inhibitors. The same amounts of protein from each sample were
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FIGURE 2 | (A) Centrosomes of cultured WT fibroblasts were stained with an
antibody raised against γ-tubulin (in red). (B) Centrosomes of cultured S3
transgenic fibroblasts were stained with an antibody raised against γ-tubulin
(in red). An abnormal number of centrosomes could be observed. (C) Nuclear
volumes of S3 fibroblasts and S3 fibroblasts treated either with KN93 or
KN62 were evaluated after DAPI staining, using ImageJ software.
(D) Fibroblasts from WT, S3, and S3 treated with KN93 were cultured and the
percentages of cells with one centrosome (white), two centrosomes (red),
and more than two (blue) were determined. This analysis has been repeated
three times. ∗∗∗p-value < 0.001.
resolved under denaturing and reducing conditions on 4–12%
NuPAGE gels (Invitrogen) and transferred to polyvinylidene flu-
oride membranes. Immunoreactive proteins were revealed by
enhanced chemiluminescence with ECL (Perkin-Elmer). An anti-
body against phosphorylated CamKII (Cell Signaling, catalog
number: 3361) was used.
NUCLEAR VOLUME EVALUATION
Nuclei were stained with DAPI. Surface of nuclei stained with
DAPI, were evaluated using ImageJ software. Average nuclear vol-
ume was evaluated using the same software. 100 DAPI stained
nuclei were analyzed in 4 independent preparations.
CENTROSOME LABELING
Cells were grown on glass coverslips for 24 h to allow cul-
tures to reach 80% confluence. To measure the number of cen-
trosomes, cells were fixed with 4% PFA, permeabilized with
methanol at −20◦C for 8min and blocked with 0.5% Triton
X-100 in PBS for 30min at RT. To detect γ-tubulin, cells were
incubated overnight at 4◦C with a mouse anti-γ-tubulin anti-
body (GTU-88; Sigma) diluted 1/1000 in PBS containing 0.1%
milk and 0.05% Triton X-100. After washing, the cells were incu-
bated for 1 h at RT with Cy3-conjugated goat anti-mouse IgG
secondary antibody (Caltag Laboratories) diluted 1/2000 in PBS
containing 0.1% milk and 0.05% Triton X-100. The prepara-
tions were counterstained with DAPI in Vectashield mounting
medium (Vector Laboratories). Fluorescent images were acquired
with a microscope (Leica DMR) equipped with a PL APO
objective.
CONNEXON ACTIVITY
One hundred thousand cells were cultured as described above
for 1 day with or without CamKII inhibitors (KN62 or
KN93 at a final concentration of 10μM). Lucifer yellow (LY)
was added to the medium (final concentration: 110μM) and
incubated for 2 h. Fluorescence was recorded using a Perkin
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FIGURE 3 | Connexon activity of WT mouse fibroblasts (A), S3
transgenic mouse (B) and S3 incubated with KN93 (C), were
incubated with LY for 2h and examined under a fluorescent
microscope. (D) Connexon activity in fibroblasts from WT, S3, and S3
treated with KN93 was monitored in a 96 well plate assay, using lucifer
yellow as a fluorescent dye (see methods). Fluorescence is in arbitrary
units. (E) Sciatic nerves, isolated either from Wild type mice (WT) or from
S3 transgenic mice, have been cultured for 24 h without or with KN93, a
CamKII inhibitor. Connexon activity has been evaluated using internalization
of LY (see Methods). ∗∗∗p-value < 0.001.
Elmer Victor 4 microplaque reader (excitation: 405 nM, emission:
535 nM).
CONNEXON ACTIVITY IN NERVES
This methods has been derived to a recently methods developed
in the laboratory (Bordignon et al., 2013). Sciatic nerves of WT
or S3 mice were surgically extracted, rinsed in PBS and deposited
in 12 wells microplates containing a specific medium composed
of RPMI 1640 with 25mM HEPES supplemented with 15% fetal
bovine serum and 100U/ml penicillin, 100 lg/ml streptomycin
(GIBCO). Microplates were incubated at 37C in 5% CO2/95%
air with or without CamKII inhibitor (KN93). We checked that
nerves anatomy was not affected by incubation (Supplementary
Figure 1) as we already described (Bordignon et al., 2013).
Lucifer yellow (1mM) were added and nerves incubated during
4 h. Medium is removed, nerves rinsed with PBS and placed
in 96 wells plates containing 200μl of medium. Fluorescence
was recorded using a Perkin Elmer Victor 4 microplaque reader
(excitation: 405 nM, emission: 535 nM).
Pim1 INHIBITORS AND BIOLOGICAL EVALUATION
Two Pim1 inhibitors have been used. Pim-1 inhibitor 1
(p1) is a 3-Cyano-4-phenyl-6-(3-bromo-6-hydroxy)phenyl-
2(1H)-pyridone,2-Hydroxy-3-cyano-4-phenyl-6-(3-bromo-6-
hydroxyphenyl)pyridine (Calbiochem, Millipore) and Pim-1
inhibitor2 (p2) is a 4-[3-(4-Chlorophenyl)-2,1-benzisoxazol-5-
yl]-2-pyrimidinamine (Tocris, biochemicals). Biological analysis
are described in this paragraph.
ANIMAL TREATMENT
Transgenic animals received intraperitoneal injections, either
with a placebo (0.9% physiological serum) or with KN 93
(1.5mg/kg). Treatment took place every day for 1 month.
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ROTAROD TEST
Global evaluation of locomotor behaviuor was performed using
the rotarod test, requiring motor coordination and balance
control. A machine manufactured by Bioseb was used for this
purpose. A previously used procedure (Mones et al., 2012) was
adapted and two velocities (15 and 25 rpm) were used. Briefly,
each mouse underwent the same 5-day procedure. The first 2 days
were used to train the animals (five sessions of 2-min walking at
a very low speed, i.e. five rotations per minute (r.p.m.)). The last
3 days were used to run the test sessions. Each day, the mice per-
formed two series of five trials, a training speed with a 1-h rest
period between the two series and a 5-min rest period between
Table 1A | Nuclear volume correction.
Mouse lines WT S3 S3 + KN62 S3 + KN93 S3 + KN92
Nuclear volume 8607 ± 508 15029 ± 690 10100 ± 729 11000 ± 540 15010 ± 550
Fibroblasts from Wild type (WT) and S3 transgenic mouse have been cultured for 24 h with or without CamKII inhibitors (KN62 and KN93). KN 92 a molecule
similar to KN93 but inactive on CamKII, has also been used. Nuclear volume has been evaluated using the Imagej software. Data have been analyzed using the
Mann-Whitney test, demonstrating that differences are not statistically different between cells treated with KN92 and wild type but are highly statistically significant
between non-treated and cells treated either with KN62 or KN 93. (p-Value < 0.0001). This experiment has been repeated three time.
Table 1B | Nuclear volume correction.
Mouse lines WT G2 G2 + KN62 G2 + KN93 G2 + KN92
Nuclear volume 8607 ± 508 14000 ± 580 9950 ± 695 9900 ± 532 15000 ± 530
Fibroblasts from Wild type (WT) and G2 transgenic mouse have been cultured for 24 h with or without CamKII inhibitors (KN62 and KN93). KN 92 a molecule
similar to KN93 but inactive on CamKII, has also been used. Nuclear volume has been evaluated using the Imagej software. Data have been analyzed using the
Mann-Whitney test, demonstrating that differences are not statistically different between cells treated with KN92 and wild type but are highly statistically significant
between non-treated and cells treated either with KN62 or KN 93. (p-Value < 0.0001). This experiment has been repeated three time.
Table 2A | Number of centrosomes per cell.
Mouse lines WT S3 S3 + KN 62 S3 + KN 93 S3 + KN92
1 Centro 79% 60% 62% 73% 60%
2 Centro 18 22 32 20 20
> Centro 3 18 6 7 20
Fibroblasts from WT and S3 have been cultured with or without CamKII inhibitors. Centrosome number per cell has been evaluated as described in methods.
Results have been analyzed using the Chi2 trends for tendency test demonstrating that data distribution is highly significant between treated and non-treated cells
(p-value < 0.0001). This experiment has been repeated three time.
Table 2B | Number of centrosomes per cell.
Mouse lines WT G2 G2 + KN 62 G2 + KN 93 G2 + KN92
1 Centro 79% 61% 70% 71% 60%
2 Centro 18 27 24 21 24
> Centro 3 12 6 8 16
Fibroblasts from WT and G2 have been cultured with or without CamKII inhibitors. Centrosome number per cell has been evaluated as described in methods.
Results have been analyzed using the Chi2 trends for tendency test demonstrating that data distribution is highly significant between treated and non-treated cells
(p-value<0.0001). This experiment has been repeated three time.
Table 3 | Fibroblasts from WT and S3 (treated or not with KN93) have been cultured for 2 days in 96 wells microplaques.
Mouse lines WT S3 S3 + KN93 G2 G2 + KN93
LY intensity 63 ± 17 17 ± 5 28 ± 9 24.5 ± 6 43 ± 7
Lucifer yellow has been then added to the medium and fluorescence monitored after 2 h (cell auto fluorescence and fluorescence of LY without cells, have been
evaluated and substracted). This experiment has been repeated three time.
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FIGURE 4 | Impact of Pim1 inhibitors on genomic instability and
connexon activity of transgenic cells. Cells from wild type animals
(WT) or from S3 transgenic line, have been incubated without or with
2 different Pim-1 inhibitors (P1, and P2, see Methods). Nuclear volume
(A), cenrosome over duplication (B) or connexon activity (C) have been
evaluated. ∗∗p-value < 0.01; ∗∗∗p-value < 0.001.
two consecutive trials. The software provided by Bioseb (Sedacom
v1) was used to monitor the time the animals were on the rod.
STATISTICAL ANALYSIS
Statistical analysis was performed using Prism v5.0. Mann-
Whitney and chi-square tests were used for trend analysis. The
significance threshold was p < 0.05. ∗p-value < 0.05, ∗∗p-value
< 0.01, and ∗∗∗p-value< 0.001.
RESULTS
TRANSGENIC Gjb1 LINES PRESENT GENOMIC INSTABILITY
The mutations G12S and S26L were introduced into the GJB1
gene contained in a human BAC (RP11-485H3) using homol-
ogous recombination in E. coli (Warming et al., 2005). The
recombinant BACs containing the mutated GJB1 gene were
injected into the oocytes of B6CBF1 mice as described previously
(Huxley et al., 1996). Five transgenic founders were born; two
contained the G12S mutation (G1, G2) and three the S26L
mutation (S1, S2, S3).
In a preceding article, we explore these different lines (Mones
et al., 2012). We observed polyploidy in mitotic spread and
an increase in nuclear volume in all transgenic lines, a result
of mitotic instability that is frequently caused by centrosome
overduplication. In addition, immunostaining for γ-tubulin, a
centrosome component, revealed an increase in the number
of multi-centrosomal cells in 10–20% of transgenic fibroblasts
whereas only 1–3% of the wild type cells presented with more
than two centrosomes.
Two transgenic lines with themost copies, G2 (two copies) and
S3 (three copies), and expressing the trangene, were selected for
further experiments.
CENTROSOMES OVERDUPLICATION IS LINKED TO CamKII ACTIVITY
In 2002, Matsumoto and Maller demonstrated that CamKII
(Ca2+/calmodulin-dependent protein kinase II) activity and cen-
trosome duplication are linked as CamKII overexpression led to
centrosome over-duplication.As normal centrosome duplication
is essential for genomic stability, we evaluated CamKII activ-
ity in cells from normal or transgenic lines. Myelinating mature
Schwann cells are not proliferative, difficult to isolate and to
culture, leading us to instead use fibroblasts isolated from trans-
genic lines. Figures 1A,B Show that the phosphorylated form
of CamKII is strongly increased in S3 fibroblasts, indicating
enzymatic overactivity in transgenic lines, and Figures 2A,B and
3B show the correlated centrosome overduplication. In order
to validate these results and to investigate a method to rescue
the cellular phenotype (centrosome overduplication), fibroblast
cell lines derived from transgenic animals were incubated with
two reference CamKII inhibitors, KN93 and KN62 (Tokumitsu
et al., 1990; Sumi et al., 1991). In addition, KN92, a very close
analog of KN93 differing only by an OH side chain but pre-
senting no CamKII inhibitory activity, was used as a negative
control. In the absence of CamKII inhibitor, all transgenic fibrob-
lasts presented aneuploidy detected by evaluation of the nuclear
volume. Figure 2C and Tables 1A,B show that treatment with
either KN62 or KN93 resulted in restitution of normal nuclear
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FIGURE 5 | (A) Nine months old mice from the G2 line were treated either
with a placebo (4 animals) or with soluble KN93 (4 animals, 1.5mg/kg, i.p., 1
administration per day) for one month and performances on the rotarod
evaluated. Treatment was then stopped and locomotor performances
evaluated one month later. (B) Same as in (A) but using the S3 line.
∗∗∗p-value < 0.001.
volume. Similarly, evaluation of centrosome numbers in these
lines show that treatment with either KN93 or KN62 revert
them close to normal numbers (Figure 2D and Tables 2A,B). In
contrast, abnormal centrosome number per cell is unchanged
in cells treated with KN92. These results strongly suggest that
involvement of Cx32 in chromosome stability is mediated
through centrosome duplication, involving the CamKII signaling
pathway.
CONNEXON ACTIVITY IS IMPAIRED IN TRANSGENIC LINES AND
CORRECTED BY CamKII INHIBITORS
To test the effect of CamKII inhibitors on connexon activity
impaired by Cx32 mutations we analyzed connexon activity in
WT and transgenic fibroblasts with KN93. The assay uses lucifer
yellow dye (LY) which becomes fluorescent upon internalization
by cells, thus specifically indicating connexon activity. If CamKII
overstimulation is linked to anomalies of connexon activity, par-
tial inhibition of CamKII would be expected to restore some, if
not all, connexon activity. We observed that connexon activity is
severely reduced in transgenic cells, and is significantly improved
upon treatment with KN93 (Figures 3 A–D, and Table 3). These
data suggest that CamKII activity and connexon activity are
probably linked.
To test these results on in vivo phenotype, we developed
a method to test connexon activity in sciatic nerves surgically
removed from mice (for details see Methods). In brief, nerves
were surgically removed, rinsed, and incubated in a specific
medium for 24 h with or without CamKII inhibitor (KN93) and
connexon activity evaluated using LY internalization. To account
for variations in tissues compared to cells, testing was done on a
larger number of nerves (12 nerves from 6 individuals). Results
are presented in Figure 3E, and nerve integrity after incubation
presented in supplementary Figure 1. We observed that con-
nexon activity is reduced in S3 nerves and partially restored in
S3 nerves treated with KN93. These data demonstrate that reduc-
tion, and partial restoration, is not restricted to fibroblasts but
also observed in sciatic nerves.
IS THE KINASE Pim-1 INVOLVED IN MITOTIC INSTABILITY OF Gjb1
TRANSGENIC LINES?
A recent report (Gao et al., 2013) indicated that CamKII
inhibitors, directly or indirectly, inhibits several other kinases,
including Pim1, a kinase that has been associated with genomic
instability in cancers (Roh et al., 2003, 2005). We incubated cells
from S3 transgenic lines with and without two different Pim1
inhibitors (see methods). Nuclear volume, centrosome over-
duplication, and connexon activity were analyzed and the results
are presented in Figure 4. We observed that incubation of cells
with Pim1 inhibitors significantly corrects nuclear volume as well
as centrosome overduplication. However, a comparable rescue of
connexon activity was not observed.
DEGRADATION OF IN VIVO BEHAVIORAL PHENOTYPE IS LOWERED BY
TREATMENT WITH CamKII INHIBITORS
Charcot-Marie-Tooth type X is a clinically heterogeneous group,
with great variability of phenotypes, mainly involving anomalies
in the peripheral nervous system with both demyelinating and
axonal features (Bergoffen et al., 1993; Hanemann et al., 2003)
However, several families have been described where a muta-
tion of Cx32 segregates and presents a central nervous phenotype
(Hanemann et al., 2003; Stancanelli et al., 2012; Al Mateen et al.,
2013).
Therefore, we analyzed the impact of KN93 treatment on the
behavioral phenotype already observed (Mones et al., 2012) in
our transgenic models using the rotarod test. The S3 and G2
transgenic mouse lines present impairment appearing at about
7 months of age and progressing with age (Mones et al., 2012).
These lines were treated with a soluble form of KN93 (1.5mg/kg
i.p. per day) and, as shown in Figures 5A,B and Tables 4, 5,
resulted in significantly lowered progression of the phenotype.
When KN93 treatment was stopped after 1 month, rapid degra-
dation of the phenotype ensued. In contrast, placebo-treated
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animals still presented progressive degradation of the phenotype
with age.
DISCUSSION
We recently demonstrated (Mones et al., 2012) that connexin
32, involved in the X-linked form of Charcot-Marie-Tooth dis-
ease, is involved in mitotic stability. Expression of a mutated allele
as wellas deletion of Gjb1 resulted in mitotic instability in our
transgenic line, in cells from animals (Mones et al., 2012). The
same situation is observed in CMTX patients, that present point
mutations (frequent), duplication or deletion (rare) of Gjb1. We
suggested here that this instability is due to CamKII overex-
pression, leading to centrosome overduplication. Matsumoto and
Maller (2002) demonstrated the relation between calcium flux,
CamKII activity, and centrosome duplication.
Moreover, Torok et al. (1997) identified two calmodulin-
binding amino-acid sequences in connexin 32 and provided
evidence that calmodulin may function as an intracellular ligand,
regulating Ca2+ dependent intercellular communication across
gap junctions. An examination of these specific calmodulin-
binding sites identified two regions, one at the N-terminus and
another one at the C-terminus, showing calcium-independent
calmodulin-binding properties (Ahmad et al., 2001). Using a
truncation mutant Cx32D215 they demonstrated that amino acid
sequences in the third transmembrane domain and a calmodulin-
binding domain in the cytoplasmic tail of Cx32 are likely candi-
dates for regulating connexin oligomerization. Finally Dodd et al.
demonstrated that this physical proximity of Cx32 and CamKII
has a physiological role (Dodd et al., 2008).
It is therefore likely that pathological mutations in Cx32, asso-
ciated to CMTX, result in mitotic instability through CamKII
overexpression leading to centrosome overduplication. It has
been observed by us (Mones et al., 2012) and by the European
Mitocheck project (www.mitocheck.org) that a lowering of Cx32
expression or expression of a mutated isoform resulted in
perturbation in cell division. Control of cell division is a key event
in Schwann cell division. Moreover, perturbation of cell division
has been associated to defects in myelination in experimental
models as well as in patient nerves.
In this report, we demonstrated that treatment with CamKII
inhibitors (KN62 or KN93) resulted in a partial rescue of the cel-
lular phenotype (abnormal centrosome overduplication, mitotic
instability, and connexon activity). This strongly suggests that
CamKII activity, genomic instability and connexon activity are
linked as defects in one of these processes led to defects in the oth-
ers. In addition, rectifying one of these processes led to restoration
of the others. This is consistent with references cited above,
demonstrating physical proximity of connexins and CamKII in
the cellular membrane. In addition, in vivo KN93 treatment
of CMTX-related transgenic mice, although not fully correct-
ing the degenerative behavioral phenotype, significantly lowered
the degradation of performances. It has been suggested that it
is through loss of function that pathogenicity of Cx32 muta-
tions plays a role (Sargiannidou et al., 2009). However, CMTX
phenotype expressed in human females suggests that a mutated
allele expressed together with a normal allele (there is no bias in
chromosome X inactivation regarding Gjb1) still leads to a patho-
logical phenotype. This is consistent with our observations and
model.
However, there is obviously a difference between the
Cx32/CamKII complex and mitotic instability. Among the dif-
ferent kinase targets of KN inhibitors, we select the Pim1 ser-
ine/threonine kinase (Gao et al., 2013) because it is involved in
mitotic instability in cancer cells (Roh et al., 2003, 2005). This
instability is linked to anomalies in the mitotic spindle and cen-
trosome overduplication (Roh et al., 2003). Treatment of our
transgenic cells with inhibitors of Pim1 significantly corrects
genomic instability, suggesting that genomic instability in cells
Table 4 | Mouse from the G2 transgenic line have been treated either with a placebo (4 animals) or with soluble KN93 (4 animals).
G2 line T0 placebo treated placebo + 1 month arrest treated + 1 month arrest
Mean minutes on rotarod 3.90 3.20 3.6 2.84 2.9
St error 0.2 0.15 0.22 0.28 0.28
Locomotor performances of the animals have been evaluated using the rotarod test after one month of treatment. Performances of WT and G2 treated with KN93,
are not statistically different. On the contrary performances of G2 animals treated either with a placebo or with KN93 are highly statistically significant (p-value <
0.0001). Treatment has been stopped for 1 month and rotarod performances evaluated. Rotarod performances of KN 93 treated or placebo treated degrade and are
not statiscally different.
Table 5 | Mouse (4) from the S3 transgenic line have been treated either with a placebo or with soluble KN93.
S3 line T0 placebo treated placebo + 1 month arrest treated + 1 month arrest
Mean minutes on rotarod 2.7 2.1 2.5 1.5 1.41
St error 0.28 0.13 0.11 0.23 0.29
Locomotor performances of the animals have been evaluated using the rotarod test after one month of treatment. Performances of WT and S3 treated with KN93,
are not statistically different. On the contrary performances of S3 animals treated either with a placebo or with KN93 are highly statistically significant (p-value <
0.0001). Treatment has been stopped for one month and rotarod performances evaluated. Rotarod performances of KN 93 treated or placebo treated degrade and
are not statistically different.
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expressing mutated alleles of Gjb1 could involve Pim1. However,
since CamKII is a membrane protein but Pim1 has been located
in cytoplasm and nucleus, this suggests a downstream role for
Pim1. In addition, if anomalies in the Cx32/CamKII complex act
on Pim1, a proto-oncogene, it could explain observations report-
ing high incidence of tumors in Cx32 null mice (Temme et al.,
1997). However, we did not observe a significant correction of
connexon activity with Pim1 inhibitors, suggesting that Pim1 is
likely a downstream player.
In vivo KN93 treatment of transgenic mice, although not
fully correcting the degenerative phenotype, significantly low-
ered the degradation of performances of transgenicmice observed
in rotarod tests. We did not know how anomalies in CamKII,
due to mutations in Cx32, could be involved in anomalies in
myelination and maturation of glial cells. However, a recent
paper (Waggener et al., 2013) could give a clue to answer the
question. This group demonstrated that CamKIIβ regulates mat-
uration of oligodendrocytes in CNS and myelination, using mice
knockouts for this gene. This function is probably mediated
through a cytoskeleton-stabilizing role.We infer that anomalies in
mitotic spindle, derived from the cytoskeleton, are also involved
in mitotic instability. We thus postulate that a cascade including
Cx32-CamKII-Pim1 is involved in PNS maturation and myelina-
tion. Anomalies in this cascade lead to reduction in myelination
and Schwann cells maturation.
Regarding therapeutic development, it is too early to apply
directly our results to the human pathology. Additional work
needs to be performed, specially using patients cells to validate
the phenomenon in human pathology. Toward this end, our work
reported here provides the first viable template to revert CMTX
phenotype in humans.
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